All In Biotech

Drug Trial Radar · NCT03547908

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 244 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

244

Actual

Start

May 30, 2018

Primary completion

Feb 25, 2022

Study completion Mar 7, 2024

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jun 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve and HIV-1 and hepatitis B virus (HBV) adults.

Conditions

  • HIV-1/HBV Co-Infection

Interventions

  • B/F/TAFDrug

    50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food

  • Placebo to match DTGDrug

    Tablet administered orally once daily, without regard to food

  • Placebo to match F/TDFDrug

    Tablet administered orally once daily, without regard to food

  • DTGDrug

    50 mg tablet administered orally once daily, without regard to food

  • F/TDFDrug

    200/300 mg tablet administered orally once daily, without regard to food

  • Placebo to match B/F/TAFDrug

    Tablet administered orally once daily, without regard to food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm (Co-primary Endpoint)Time frame: Week 48
  2. Percentage of Participants With Plasma Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 as Defined by Missing = Failure Approach (Co-primary Endpoint)Time frame: Week 48

Locations

69 sites in 14 countries. Site status is shown where the registry gives one.

  • Midway Immunology & Research

    Ft. Pierce, Florida

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida

  • Be Well Medical Center

    Berkley, Michigan

  • The Crofoot Research Center, INC (DBA: Gordon E. Crofoot MD PA)

    Houston, Texas

  • Beijing Ditan Hospital Capital Medical University

    Beijing, China

  • Beijing YouAn Hospital, Capital Medical University

    Beijing, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China

  • The First Hospital of Changsha

    Changsha, China

  • Chengdu Public Health Clinical Center

    Chengdu, China

  • Guangzhou Eighth people's Hospital

    Guangzhou, China

  • 1st Affiliated Hospital of Zhejiang University

    Hangzhou, China

  • The Second Hospital of Nanjing

    Nanjing, China

  • Shanghai Public Health Clinical Center

    Shanghai, China

  • Third People's Hospital Of Shenzhen

    Shenzhen, China

  • Instituto Dominicano de Estudios Virologicos (IDEV)

    Santo Domingo, Dominican Republic

  • Hôpital de la Croix Rousse

    Lyon, France

  • Evaggelismos General Hospital of Athens

    Athens, Greece

  • Korgialenio-Benakio Greek Red Cross General Hospital

    Athens, Greece

  • Laiko General Hospital

    Athens, Greece

  • AHEPA University Hospital of Thessaloniki

    Thessaloniki, Greece

  • Prince of Wales Hospital

    Hong Kong, Hong Kong

  • Queen Elizabeth Hospital (QEH)

    Hong Kong, Hong Kong

  • Princess Margaret Hospital

    Kowloon, Hong Kong

  • National Hospital Organization Nagoya Medical Center

    Aichi, Japan

  • University of the Ryukyus Hospital

    Okinawa, Japan

  • Osaka City General Hospital

    Osaka, Japan

  • National Hospital Organization Osaka National Hospital

    Osaka, Japan

  • The Jikei University Hospital

    Tokyo, Japan

  • Juntendo University Hospital

    Tokyo, Japan

  • Center Hospital of the National Center for Global Health and Medicine

    Tokyo, Japan

  • Yokohama City University Hospital

    Yokohama, Japan

  • Hospital Raja Permaisuri Bainun

    Ipoh, Malaysia

  • Hospital Raja Perempuan Zainab II

    Kota Bharu, Malaysia

  • Queen Elizabeth Hospital

    Kota Kinabalu, Malaysia

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Hospital Kuala Lumpur

    Kuala Lumpur, Malaysia

  • Hospital Sultanah Nur Zahirah

    Kuala Terengganu, Malaysia

  • Sarawak General Hospital

    Kuching, Malaysia

  • Hospital Pulau Pinang

    Pulau Pinang, Malaysia

  • Sungai Buloh Hospital

    Sungai Buloh, Malaysia

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.